T
TC BioPharm Ltd
NASDAQ:TCBP
TC BioPharm Ltd
NASDAQ:TCBP
Price:
0.5
USD
-67.53%
Market Cap:
$63k
Relative Value
There is not enough data to reliably calculate the relative value of TCBP.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TCBP
Relative Value
Base Case
Not Available
Multiples Across Competitors
TCBP Competitors Multiples
TC BioPharm Ltd Competitors
TC BioPharm Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
T
|
TC BioPharm Ltd
NASDAQ:TCBP
|
63k USD | 0 | -0 | 0.1 | 0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
405.8B USD | 6.6 | 96.9 | 15.9 | 22.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.2B USD | 5.3 | 25.3 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
178.1B USD | 6.1 | 21 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.9B USD | 9.7 | 29.4 | 22.1 | 23.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.8B AUD | 3.3 | 35.9 | 11.8 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.7B EUR | 10.9 | 35.1 | 38.1 | 38.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
